ArticleJournal of clinical microbiology2021
Xpert MTB/XDR: a 10-Color Reflex Assay Suitable for Point-of-Care Settings To Detect Isoniazid, Fluoroquinolone, and Second-Line-Injectable-Drug Resistance Directly from Mycobacterium tuberculosis-Positive Sputum.
Article in Journal of clinical microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.
- Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.The Cochrane database of systematic reviews · 2022Pooled it
- Melting temperature signatures reveal occasional misclassification of low-level isoniazid resistance by Xpert MTB/XDR.Microbiology spectrum · 2026Article
- Research on Gut Microbiota Features and Potential Biomarkers in Patients with Pulmonary Tuberculosis.Pathogens (Basel, Switzerland) · 2026Article
- Xpert MTB/XDR performance in non-sputum samples for diagnosis of drug-resistant tuberculosis at a North Indian tertiary care center.Journal of clinical microbiology · 2026Article
- Rapid drug susceptibility testing of Mycobacterium tuberculosis against first-line drugs simultaneously all-in-one plate by using a novel high-sensitive reporter phage combined with the BACTEC MGIT 960 system.Infectious diseases of poverty · 2026Article
- A cartridge-based assay for improved detection of multidrug-resistantJournal of clinical microbiology · 2026Article
- Real-World Assessment of the Xpert MTB/XDR for Detecting Isoniazid and Second-Line Drug Resistance Among TB Patients.International journal of molecular sciences · 2026Article
- Multicentre field evaluation of Xpert MTB/XDR in sub-Saharan Africa.ERJ open research · 2026Article
- Tuberculosis Diagnostic Methods: Clinical Applicability, Implementation Challenges, and Integrated Testing Strategies.Pathogens (Basel, Switzerland) · 2026Review
- Development of a point-of-care dual one-step recombinase-aided PCR assay for rapid identification ofFrontiers in microbiology · 2026Article
- From mutation detection to treatment decisions: CRISPR-enabled diagnostics for drug-resistant tuberculosis.Frontiers in bioengineering and biotechnology · 2026Review
- Rapid Molecular Diagnostics of Tuberculosis: What Do We Have, What Do We Need?Pulmonary medicine · 2026Review
- pHEAA/pMA-DNA Hydrogel Sensing Platform for Detecting Drug-Resistant Gene Variants inACS measurement science au · 2025Article
- Identification and quantification ofJournal of clinical microbiology · 2025Article
- Reliable, accessible, cost-effective, & easy (RACE) diagnostic modality: A key for elimination of tuberculosis.The Indian journal of medical research · 2025Review
- Drug resistance profile of Mycobacterium tuberculosis complex isolated from pulmonary tuberculosis patients and their household contacts in central Ethiopia.BMC infectious diseases · 2025Article
- Phenotypic drug susceptibility testing for Mycobacterium tuberculosis variant bovis BCG in 12 hours.Nature communications · 2025Article
- Drug-resistant tuberculosis profiles among patients presenting at the antituberculosis center of Brazzaville, Republic of Congo.Annals of clinical microbiology and antimicrobials · 2025Article
- Detection of extensive drug resistance by the Xpert MTB/XDR assay in multidrug resistant tuberculosis cases at a tertiary care centre in northern India, and therapeutic decision making for the six-month BPaLM regimen.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Article
- Xpert MTB/XDR Assay for Detection of Resistance to Isoniazid, Fluoroquinolone, Aminoglycoside, and Ethionamide Among Patients with Pulmonary Tuberculosis in Bangladesh.Infectious diseases and therapy · 2025Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
Abstract
We describe the design, development, analytical performance, and a limited clinical evaluation of the 10-color Xpert MTB/XDR assay (CE-IVD only, not for sale in the United States). This assay is intended as a reflex test to detect resistance to isoniazid (INH), fluoroquinolones (FLQ), ethionamide (ETH), and second-line injectable drugs (SLIDs) in unprocessed sputum samples and concentrated sputum sediments which are positive for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.